surpass cvot tirzepatide Comparison of and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics SURPASS-CVOT — Leicester Diabetes Centre

Patients are eligible for treatment if they have at least one weight-related comorbidity, such as hypertension or cardiovascular disease, and either a BMI of at least 35 or a BMI of 30 to 34.9

Its not cheating or a lazy persons out. She and others interviewed for this story emphasized that GLP-1s must be paired with lifestyle changes and counseling, particularly to avoid deficiencies of key nutrients and muscle loss, and that patients should be prepared to stay on a maintenance dose long-term

Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use these medications

It is important to note that in the current middle-aged population, there is a significant proportion of individuals with type 2 diabetes and obesity